May 1, 2018 / 11:44 AM / a month ago

BRIEF-FDA Releases Theratechnologies From Post-Approval Commitments Related To EGRIFTA

May 1 (Reuters) - Theratechnologies Inc:

* FDA RELEASES THERATECHNOLOGIES FROM POST-APPROVAL COMMITMENTS RELATED TO EGRIFTA® (TESAMORELIN FOR INJECTION)

* THERATECHNOLOGIES - FDA DETERMINED LARGE-SCALE POST-APPROVAL TRIALS NO LONGER REQUIRED AS CURRENT LABELING ADEQUATELY REFLECTS SAFETY PROFILE OF EGRIFTA

* THERATECHNOLOGIES - FOR YEAR ENDED NOV 30, 2017, CO ESTIMATED POST-APPROVAL COMMITMENTS WILL REQUIRE $13 MILLION INVESTMENT, WHICH WILL NO LONGER BE NEEDED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below